Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael E Pollock

Showing results (191-200 of 234) with videos related to

Pageof 24
Sort By:
Cancer|July 17, 2015
Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcomaWilliam W Tseng, Shouhao Zhou, Christina A To, et al.
Annals of Surgical Oncology|March 30, 2002
Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapyNadeem Q Mirza, Georges Vlastos, Funda Meric, et al.
Cancer Research|September 14, 2018
The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced CachexiaFederica Calore, Priya Londhe, Paolo Fadda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated LiposarcomaKate Lynn J Bill, Jeannine Garnett, Isabelle Meaux, et al.
Cancer|May 17, 2002
Tumor volume as a prognostic factor for sarcomatosisMalcolm M Bilimoria, Daniel J Holtz, Nadeem Q Mirza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated LiposarcomaKate Lynn J Bill, Jeannine Garnett, Isabelle Meaux, et al.
Annals of Surgical Oncology|December 11, 2012
Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancerKeila E Torres, Vinod Ravi, Katherine Kin, et al.
Plos One|September 17, 2025
Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicingAbeba Zewdu, Danielle Braggio, Gonzalo Lopez, et al.
Annals of Surgical Oncology|March 7, 2015
Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic LesionsSean P Dineen, Christina L Roland, Rachel Feig, et al.
Molecular Therapy. Oncology|April 10, 2024
Progress in sarcomas: Highlights from the 2023 annual meetingof the Connective Tissue Oncology SocietyTimothy P Cripe, Ryan D Roberts, Dawn S Chandler, et al.
Pageof 24

Showing results (191-200 of 234) with videos related to

Sort By:
Pageof 24
Cancer|July 17, 2015
Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcomaWilliam W Tseng, Shouhao Zhou, Christina A To, et al.
Annals of Surgical Oncology|March 30, 2002
Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapyNadeem Q Mirza, Georges Vlastos, Funda Meric, et al.
Cancer Research|September 14, 2018
The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced CachexiaFederica Calore, Priya Londhe, Paolo Fadda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated LiposarcomaKate Lynn J Bill, Jeannine Garnett, Isabelle Meaux, et al.
Cancer|May 17, 2002
Tumor volume as a prognostic factor for sarcomatosisMalcolm M Bilimoria, Daniel J Holtz, Nadeem Q Mirza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated LiposarcomaKate Lynn J Bill, Jeannine Garnett, Isabelle Meaux, et al.
Annals of Surgical Oncology|December 11, 2012
Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancerKeila E Torres, Vinod Ravi, Katherine Kin, et al.
Plos One|September 17, 2025
Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicingAbeba Zewdu, Danielle Braggio, Gonzalo Lopez, et al.
Annals of Surgical Oncology|March 7, 2015
Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic LesionsSean P Dineen, Christina L Roland, Rachel Feig, et al.
Molecular Therapy. Oncology|April 10, 2024
Progress in sarcomas: Highlights from the 2023 annual meetingof the Connective Tissue Oncology SocietyTimothy P Cripe, Ryan D Roberts, Dawn S Chandler, et al.
Pageof 24